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Dr Ruttmanndoi:10.1016/j.jtcvs.2005.03.016Objectives: Mitral repair in active infective endocarditis still remains controversial.
Several studies demonstrate the feasibility of mitral repair in infective endocarditis;
however, superiority of repair has never been shown. The aim of the investigation was
to compare valve repair and valve replacement in respect to the extent of destruction and
to analyze survival, recurrent endocarditis, and reoperation (event-free survival).
Methods: Sixty-eight consecutive patients underwent surgical intervention for mitral
endocarditis. Thirty-four (50%) patients had valve repair, and 34 (50%) patients had
valve replacement. Leaflet destruction involving at least one mitral leaflet was
present in 15 (44.1%) patients of the repair group and 11 (32.4%) patients of the
replacement group. Repair of the mitral annulus with pericardium was performed in
4 (11.8%) patients in the repair group and 3 (8.8%) patients in the replacement
group. Patients in both groups were similar concerning the progression of valvular
destructions and comorbidities.
Results: Hospital mortality was 11.8% (8 patients). No significant differences were
found in all baseline parameters, with the exception of a higher incidence of
previous septic embolism and sepsis in the repair group. Actuarial event-free
survival at 1 year was 88.2% in the repair group compared with 67.7% in the
replacement group, and 5-year event-free survival was 80.4% in the repair group
and 54.6% in the replacement group (P  .015). Mitral valve repair remained the
superior treatment regarding event-free survival in the multivariate analysis (hazard
ratio, 0.33; 95% confidence interval, 0.12-0.93; P  .02).
Conclusions: Mitral valve repair offers excellent early and late results and is the
preferable treatment option in the surgical therapy of native infective endocarditis.
Even though there have been great improvements in general health care andantibiotic therapy, the incidence of infective endocarditis (IE) has notchanged during the past decades.1
However, there has been a shift in the clinical appearance of IE. Underlying
rheumatic valvular disease that was frequently observed in patients with IE during
the 1980s has become rare in industrialized countries.2 As a predisposing factor, it
has been replaced by other causes, such as intravenous drug abuse, immunosup-
pression, degenerative valvular disease, intravascular prostheses and devices, he-
modialysis shunt infections, and other nosocomial infections.3
Mitral valve repair is a well-established treatment for noninfected valves and
offers certain advantages. Because of preservation of the subvalvular apparatus and
the resulting restoration of left ventricular function, mitral valve repair is favorable
in the treatment of mitral regurgitation.
In mitral surgery for IE, prosthetic valve replacement has been the standard
therapy for many years. Because of the decreasing incidence of underlying rheu-
matic disease and the convincing long-term results of repair of noninfected valves,4
mitral valve repair in patients with IE is still controversial.
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that valve repair is feasible in aortic and mitral endocarditis
in 1990.
Several outcome studies6-8 have confirmed that mitral
valve repair is effective in patients with IE but were lacking
comparable matched cohorts of patients undergoing mitral
valve replacement for the same indication.6,7 Additionally,
in most studies, patients with healed endocarditis and pa-
tients with underlying rheumatic disease were investigated
and had limited sample sizes.9-11
Superiority of valve repair as a possible treatment option
for active mitral endocarditis has never been confirmed.
At the Department of Cardiac Surgery at the University
Hospital Innsbruck, a large number of patients with active
mitral endocarditis have undergone operations during recent
years. Approximately half of the patients underwent mitral
repair.
The aims of our study were (1) to investigate whether
there are differences in the extent of infectious destruction
of mitral valves undergoing either repair or replacement and
(2) to evaluate whether valve repair offers a benefit over
replacement in acute IE in respect to perioperative mortality
and long-term event-free survival.
Methods
From 1992 through 2004, a consecutive series of 74 patients
underwent cardiac operations for active IE of the native mitral
valve at the Cardiac Surgery Department of the University Hos-
pital Innsbruck. Six patients with an underlying rheumatic valve
stenosis were excluded from further analysis to avoid selection
bias because of limited chance for sufficient valve repair.
A total of 68 patients (39 [57.4%] male and 29 [42.6%] female
patients) were divided into 2 cohorts with regard to the type of
mitral valve procedure performed: 34 (50%) patients underwent
mitral valve repair, and the remaining 34 patients underwent mitral
TABLE 1. Patient characteristics
Mitra
Age, y 51.
Male sex 22
Obesity, BMI 30 kg/m2) 3
Diabetes 6
Chronic obstructive pulmonary disease 6
Impaired renal function (creatinine 2 mg/dL) 10
Preoperative kidney failure 6
Ejection fraction 49
NYHA stage (mean) 2.8
NYHA stage IV (%) 7
Previous septic embolization 15
Preexisting degenerative valvular disease 15
EuroSCORE (mean) 9
BMI, Body mass index; NYHA, New York Heart Association. *Means  Svalve replacement.
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an operation because of the failure of conservative therapy (persisting
sepsis, embolic events, and hemodynamic instability). All patients
described in our series were given diagnoses not only on the basis of
the clinical Dukes criteria but also on the basis of preoperative and
intraoperative echocardiography.12,13 Additionally, intraoperative
bacterial cultures and histology of the excised valve tissue confirmed
the diagnosis of active valvular infection.
All surgical procedures, both repair and replacement, were
performed by experienced surgeons in the position of a consultant.
From a technical aspect, radical debridement of the infective
material without consideration of the resulting lesion and, in a
second step, restoration of a morphologic and functional valve
were performed.
Event-free survival was defined as the primary outcome mea-
sure to compare efficacy. Deaths of all causes, valvular reopera-
tion, and recurrent endocarditis were regarded as events. Kaplan-
Meier analysis, together with log-rank testing, was used to
compare event-free survival between the 2 treatment options (re-
pair vs replacement). The Pearson 2 test or the Fisher exact test
(when appropriate) was used to test for baseline differences in
categoric variables. Continuous variables were tested with the
Student t test or the Mann-Whitney U test (if assumption of
Gaussian distribution was not fulfilled). The Cox proportional
hazard model was used to assess the effect of treatment indepen-
dently from other potential life-threatening predictors. Adjusted
hazard ratios (HRs) and their 95% confidence intervals (CIs) were
calculated. All variables that showed a significant effect on event-
free survival in the univariate Kaplan-Meier analysis were in-
cluded in the multivariate Cox model.
Data documentation and statistical analysis were performed
with SPSS software version 11.0 (SPSS Inc, Chicago, Ill).
Results
Patient Characteristics
The mean age of the patients was 51.5  17.0 years in the
e repair
34)
Mitral valve replacement
(n  34) P value
7.0* 53.2 13.1 .840
7%) 17 (50.0%) .383
%) 4 (11.8%) .721
6%) 6 (17.6%) .954
6%) 5 (14.7%) .701
4%) 12 (35.3%) .479
6%) 3 (8.8%) .476
12% 53% 12% .197
0.87 2.76 0.55 .968
6%) 2 (5.9%) .121
2%) 6 (17.6%) .027
2%) 12 (35.3%) .840
4.2 9.7 3.8 .760l valv
(n 
5 1
(64.
(8.8
(17.
(17.
(29.
(17.
%
0
(20.
(44.
(44.
.8repair group and 53.2 13.1 years in the replacement group
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antibiotic treatment to surgical intervention was 11 days
(0-44 days) in the repair group and 12 days (1-48 days) in
the replacement group (P  .31). The median time from
definitive diagnosis (day of transesophageal echocardiogra-
phy) to surgical intervention was 4 days (1-25 days) in the
replacement group and 3.5 days (0-21 days) in the repair
group (P  .32).
A detailed preoperative patient description is displayed
in Table 1.
Median follow-up was 37.7 months in the repair group and
44.5 months in the replacement group (P  .240). Follow-up
was performed by the referring cardiologists, including fre-
quent echocardiography, and was 100% complete.
Renal failure was present in 6 (17.6%) patients in the
repair group and 3 (8.8%) patients in the replacement group
(P  .476). Mean ejection fraction at the time of the
operation was 49%  12% in the repair group and 53% 
12% in the replacement group (P  .197).
Mean cardiopulmonary bypass time was 166  63.2
minutes in the repair group and 144.3 91.0 minutes in the
replacement group (P  .260). Aortic crossclamping time
was significantly longer in the repair group (114.3 52.3 vs
85.5  40.5 minutes, P  .014).
Underlying degenerative mitral valve disease was
present in 15 (44.2%) patients in the repair group and 12
(35.3%) patients in the replacement group (P  .820).
In the mitral repair group, however, a higher number of
patients had experienced preoperative septic embolism (ce-
rebral and peripheral) than in the replacement group (44.2%
vs 17.6%, P  .027). Additionally, sepsis as the main
indication for surgical intervention was significantly more
common in the mitral repair group (50% vs 26.1%, P 
.018). Otherwise, the 2 treatment groups did not differ
significantly concerning preoperative comorbidity, surgical
risk (assessed by the EuroSCORE), or the extent of destruc-
tion of the mitral valve (Table 2).
Additional procedures, such as coronary artery bypass
grafting, aortic valve replacement, and/or tricuspid valve
repair (caused by double-valve endocarditis), were neces-
sary in 13 (38.2%) patients in the repair group and 13
(38.2%) patients in the replacement group (P  1.0).
At the time of the operation, valves were still found to be
contaminated by infective organisms in 15 (44.1%) patients
in the repair group and 19 (55.9%) patients in the replace-
ment group (P  .332). Staphylococcus species were iso-
lated in blood, valve cultures, or both in 19 (55.9%) patients
in the repair group and 13 (38.2%) patients in the replace-
ment group (P  .145). Leaflet destruction was present in
15 (44.1%) patients in the repair group and 11 (32.4%)
patients in the replacement group (P  .394). Perivalvular
destruction and abscesses requiring annular reconstruction
with autologous glutaraldehyde-fixed pericardium were per-
The Journal of Thoraciformed in 4 (11.8%) patients in the repair group and 3
(8.8%) patients in the replacement group (P  .659). Com-
missural affection was present in 3 (8.8%) patients in the
repair group and 4 (11.7%) patients in the replacement
group (P  .73).
Mitral ring annuloplasty was performed in 19 (55.9%)
patients (Carpentier Edwards in 13 patients, Sequin in 5
patients, and St Jude Tailor in 1 patient) in the repair group.
Ring annuloplasty was indicated when sufficient coaptation
of leaflets was not achievable without it and was frequently
necessary in patients showing annular dilatation. Transpo-
sition of secondary chordae in the primary position was
performed in 4 patients, and artificial chordae were used in
1 male patient in the repair group.
In the replacement group 28 (82.4%) patients received a
mechanical mitral valve prosthesis, and the remaining 6
(17.6%) patients underwent biologic mitral valve replacement.
Perioperative Mortality
Overall perioperative mortality was 11.8% (8 patients, 4
patients in the repair group and 4 patients in the replacement
group; P  1.0).
One female patient had double-valve endocarditis (aortic
and mitral endocarditis, methicillin-resistant Staphylococcus
aureus, and Aspergillus fumigatus) and invasive pulmonary
aspergillosis after she had undergone her third kidney trans-
plantation. She underwent aortic root replacement with a por-
cine xenograft root (Freestyle; Medtronic Minneapolis, Minn)
because of destructive double-valve endocarditis and a com-
plex mitral valve repair. She died on the fifth postoperative day
of invasive aspergillosis. Another female patient was given a
diagnosis of acute mitral valve endocarditis 1 month after
successful kidney-pancreas transplantation. She had a previous
septic thromboembolic occlusion of the kidney allograft artery
and underwent an emergency operation under septic condi-
tions. After initial recovery from mitral valve repair, transplant
nephrectomy was performed on day 7 after cardiac surgery as
a result of ongoing sepsis. She died on day 42 as a result of
mucormycosis that was affecting the brain, lungs, and myo-
cardium. At autopsy, there was no recurrence of endocarditis in
either transplant patient.
Two male patients in the mitral valve repair group died
of unrestrained sepsis. In the replacement group one male
patient died of a mesenteric infarction, and 2 patients died of
uncontrollable sepsis. Another male lung transplant recipi-
ent had an early recurrence of endocarditis and died on the
fifth day after reoperation of ongoing sepsis.
Postoperative Outcome
In the repair group one recurrence of endocarditis occurred
13 months after cardiac surgery. Initially, the patient had
destruction of the posterior leaflet and underwent repair
with autologous glutaraldehyde–fixed pericardium along
c and Cardiovascular Surgery ● Volume 130, Number 3 767
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septic conditions after he had an embolic cerebral event and
received a mechanical mitral prosthesis. The patient died on
the first postoperative day of refractory sepsis. There were
no other valve-related complications or late deaths in the
repair group. In the replacement group 3 patients underwent
reoperation because of recurrence of endocarditis (2, 12,
and 19 months after the primary operation, respectively),
and 2 patients died of recurrence of infection 2 and 4
months after initial surgical treatment without undergoing
reoperation. Diagnosis of recurrence was confirmed at au-
topsy. A total of 6 cardiac-related deaths occurred in the
replacement group. Three patients died within 18 months,
and 3 patients died later in the follow-up.
A male patient underwent reoperation because of throm-
bosis of the mechanical mitral valve prosthesis and again
TABLE 2. Perioperative characteristics
Main indication for surgical intervention
Persistent sepsis
Proceeded or imminent septic embolism
Congestive heart failure
Mean mitral regurgitation (grade SD)
Positive intraoperative valve culture
Staphylococcal endocarditis
Leaflet destruction
Anterior mitral leaflet
Posterior mitral leaflet
Both leaflets
Perivalvular destruction
Chordal rupture
Commissure affected
Intraoperative characteristics
Additional surgical procedures
Coronary artery bypass grafting (procedures)
Aortic valve replacement (procedures)
Tricuspid valve repair (procedures)
Leaflet reconstruction with direct suture (procedures)
Leaflet reconstruction with glutaraldehyde-fixed pericardium patc
(procedures)
Annular reconstruction with glutaraldehyde-fixed pericardium pat
Mitral ring annuloplasty
Chordal implantation-transposition
Rectangular resection
Sliding leaflet plasty
Rotation paracommissural sliding plasty
Mechanical mitral valve prosthesis
Biologic stented mitral valve prosthesis
CPB time (min)
Aortic crossclamp time (min)
CPB, Cardiopulmonary bypass. *Mean  SD.recovered well. Another patient died of recurrence of sepsis
768 The Journal of Thoracic and Cardiovascular Surgery ● Septbut without reinfection of the valve prosthesis 3 months
after the operation.
Actuarial 1-year survival was 88.2% in the repair group
and 73.5% in the replacement group, and 5-year survival
was 85.1% in the repair group and 66.6% in the replacement
group (P  .242).
One-year freedom from valvular reoperation was 100%
in the repair group and 89.4% in the replacement group, and
at 5 years’ follow-up, it was 96.4% in the repair group and
85.5% in the replacement group (P  .146).
Actuarial freedom from recurrence of endocarditis at 5
years’ follow-up was 96.4% in the repair group and 82.7%
in the replacement group (P  .086).
Event-Free Survival
To evaluate the efficacy of both treatment groups, a com-
Mitral valve repair
(n  34)
Mitral valve replacement
(n  34) P value
17 (50%) 6 (26.1%) .005
10 (29.4%) 15 (44.1%) .2
7 (20.6%) 13 (38.2%) .11
2.8 1.2* 2.7  1.0 .957
15 (44.1%) 19 (55.9%) .332
19 (55.9%) 13 (38.2%) .145
15 (44.1%) 11 (32.4%) .394
4 (11.8%) 5 (14.7%)
9 (26.5%) 5 (14.7%)
2 (5.8%) 1 (2.9%)
6 (17.6%) 5 (14.7%) .701
12 (35.3%) 8 (23.5%) .251
3 (8.8%) 4 (11.7%) .730
13 (38.2%) 13 (38.2%) 1.0
6 (17.6%) 3 (17.6%) 1.0
6 (17.6%) 6 (17.6%) 1.0
3 (8.8%) 1 (2.9%) .760
5 (14.7%)
15 (44.1%)
4 (11.8%) 3 (8.8%) .659
19 (55.9%)
5 (14.7%)
8 (23.5%)
4 (11.8%)
3 (8.8%)
28 (82.4%)
6 (17.6%)
166.0 63.2 144.3 91.0 .260
114.3 52.3 85.5 40.5 .014h
chposite end point consisting of survival, reoperation, and/or
ember 2005
Ruttmann et al Surgery for Acquired Cardiovascular Disease
A
CDrecurrence of endocarditis was defined to investigate free-
dom from treatment failure.
Actuarial event-free survival at 1 year was 88.2% in the
repair group and 67.7% in the replacement group, 5-year
event-free survival was 80.4% in the repair group and
54.6% in the replacement group, and 10-year event-free
survival was 80.4% in the repair group and 46.2% in the
replacement group (P  .015, Figure 1).
Prognostic Factors of Event-Free Survival
Several clinical parameters referring to preoperative comor-
bidity and endocarditis-related findings were univariately
tested for their effect on event-free survival.
Demographic factors, such as age (P .640) or sex (P
.540), did not have an influence on event-free survival nor
did valve-related parameters, such as staphylococcal infec-
tion (P  .220), sepsis as an indication for surgical inter-
vention (P  .56), positive valve cultures at surgical inter-
vention (P  .404), or preoperative septic embolism (P 
.912), or renal dysfunction at surgical intervention (P 
.120).
However, impaired left ventricular function (ejection
fraction48%) at surgical intervention was associated with
poor event-free survival (P  .002), as well as additional
surgical procedures, such as coronary artery bypass grafting
or other valve procedures (P  .035).
Adjusting for these variables in the multivariate analysis,
mitral valve repair remained the superior therapy regarding
event-free survival compared with valve replacement (HR,
0.33; 95% CI, 0.12-0.93; P .02). In addition, impaired left
ventricular function at surgical intervention was indepen-
dently affecting the event-free survival (HR, 3.0; 95% CI,
1.099-8.42; P  .046). However, contrary to univariate
analysis, the need for additional surgical procedures did not
predict a difference in event-free survival by means of
multivariate analysis (HR, 2.1; 95% CI, 0.88-5.2; P .092).
Discussion
Several outcome studies have confirmed the feasibility of
mitral valve repair in IE but were not able to demonstrate the
superiority of repair in a severity-matched cohort.6,9,11,14,15
Additionally, this is the largest consecutive series of patients
described undergoing mitral valve repair in active infection.
To our knowledge, this is the first study demonstrating a
significantly improved event-free survival of mitral valve
repair over replacement in comparable groups of patients
with severe native mitral endocarditis. Even though we
found a similar extent of valvular destruction and paraval-
vular lesions and a significantly higher incidence of septic
embolism in the repair group, valve repair was an indepen-
dent predictor of event-free survival.
In contrast to other studies,7,9-11 we only included pa-
tients with active mitral valve endocarditis and no patients
The Journal of Thoraciwith healed endocarditis. Additionally, patients presenting
with underlying rheumatic valve disease who are more
likely to undergo replacement were not included into this
study.
Muehrcke and associates10 reported a significantly better
event-free survival in the repair group, consisting of mainly
healed endocarditis, but we could not confirm this result in
the subgroup of 26 patients undergoing mitral repair for
acute endocarditis. Additionally, rheumatic valve disease
was present in their replacement group.
Although the decision for the surgical strategy is mainly
dependent on the extent of valvular and annular destruction,
we were able to perform sufficient repair, even in severely
destructed mitral valves, including annular abscesses. In
contrast to Mihaljevic and coworkers,14 who presented a
repair group undergoing operation for vegetations only in
81% of the study group, we were able to perform sufficient
repair in patients mainly presenting with severe destruction
of at least one mitral leaflet.
The use of prosthetic material in active endocarditis is
still controversial.10,16,17 However, there has never been a
study evidencing that either the choice of prosthesis (me-
chanical or biologic) or the use of a prosthetic annuloplasty
Figure 1. Kaplan-Meier event-free survival (freedom from death,
valvular reoperation, and/or recurrence of endocarditis) for patients
undergoing either mitral repair (solid line) or replacement (dashed
line) for acute mitral endocarditis (P  .015, log-rank test).ring is responsible for a higher recurrence rate of endocar-
c and Cardiovascular Surgery ● Volume 130, Number 3 769
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factor for the development of IE, optimal repair is essential
to prevent recurrence. Therefore we are routinely using
prosthetic rings in patients with annular dilatation, even
though this annuloplasty might present additional risk for
recurrent bacterial colonization. However, we are convinced
that a remaining mitral regurgitation bears a higher risk for
recurrence than a prosthetic ring annuloplasty.
In our series more than 50% of all patients received a
prosthetic mitral ring annuloplasty, and there was only one
recurrence of endocarditis in a male patient with methicillin-
resistant Staphylococcus aureus 13 months after valve re-
pair. The low recurrence rate in the repair group underlines
this strategy; however, radical debridement of all infected
and potentially infected material is a precondition.
During the past decade, hospital-acquired endocarditis
with highly aggressive micro-organisms has become more
frequent in more ill patients (eg, transplant recipients). In
our experience the predominant infective organism was
Staphylococcus species, and this organism was even more
prevalent in the repair group. In agreement with Renzulli
and associates,18 positive blood and tissue cultures were not
predictive of poor event-free survival in our study. How-
ever, in contrast to Sternik and associates,15 patients with
staphylococcal endocarditis at the time of the operation
were not more likely to undergo valve replacement in our
study. In their study the authors demonstrated excellent
results, even in patients undergoing complex repairs.
In destructive mitral endocarditis, the concept of pros-
thetic valve replacement as the established primary treat-
ment option for IE might be substantially wrong, and we
have to reassess the therapeutic concepts.
Of course, the surgeon’s experience in mitral valve repair
is essential, and only highly specialized and skilled sur-
geons would dare to repair even severely destructed mitral
valves. In our patient cohort reconstructive operations were
exclusively performed by 2 surgeons highly experienced in
mitral repair and might therefore be responsible for the
convincing results.
From clinical experience and quality control, we know
that rare surgical procedures should be limited to few sur-
geons to gain experience and excellent results. Because IE
is of growing importance in cardiac surgery, the number of
specialists in this field should increase. In general, the
surgeon’s bias might be present in all surgical case series
and could be avoided by randomization. However, we be-
lieve that forcing a surgeon to perform a procedure of which
he or she is not convinced or experienced with at a high
level might be unethical.
The restrictive attitude toward surgical intervention in
acute endocarditis has changed during the last decade. Early
operation for IE is more common today, on the one hand
because of improved results of cardiac surgery in general
770 The Journal of Thoracic and Cardiovascular Surgery ● Septand on the other hand because of the higher incidence of
more aggressive forms of endocarditis resulting in septic
embolism, perivalvular abscess, and the higher frequency of
hospital-acquired endocarditis that is mainly incurable with
conservative therapy alone.19 Additionally, in acute endo-
carditis, when the clinical course is complicated by septic
cerebral embolism, early surgical intervention is recom-
mended despite the risk of secondary cerebral hemorrhage.
Several studies have shown that the cardiac procedure ought
to be performed within 72 hours after occurrence of the
embolic event.20,21 In contrast to the results of Jault and
coworkers,22 septic embolic complications before cardiac
surgery were not associated with a poor event-free survival
in our experience.
The nonrandomized design of our study limits our con-
clusions; however, it is unlikely that randomized trials will
be feasible regarding the choice of these 2 surgical tech-
niques. Although the groups seem to be highly comparable,
it is very difficult to be sure that the characteristics of the
patients and, especially, of the valves are identical. Also, we
cannot neglect effects caused by the surgeon’s experience.
However, the significant differences in late outcome are not
related to eventual differences in surgical mortality. There-
fore it appears quite evident that the differences found are
not due to chance or bias alone.
In conclusion, even though we have to deal with more
complex forms of mitral valve endocarditis in more ill
patients today,23,24 valve repair offers excellent early and
late results in patients with active mitral valve endocarditis
and is the preferable treatment option in the surgical therapy
of native mitral endocarditis.
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